Hematology

CAR T-cell therapy represents a viable treatment option for many patients, but there are potentially serious adverse events.

Patients with acute lymphoblastic leukemia who received vincristine-based regimens with TKIs did not experience more chemotherapy-induced peripheral neuropathy vs those who did not.

A nonrestrictive diet was found to be noninferior to a protective diet in the post-stem cell transplant setting, suggesting that lifting restrictions may improve patient quality of life.

Real-world data from patient-reported outcomes suggest that axicabtagene ciloleucel is associated with temporary worsening of quality of life with statistically and clinically significant improvements within 1-year postinfusion.

Adding daratumumab to bortezomib, lenalidomide, and dexamethasone showed meaningful improvements in patient-reported outcomes in the phase 2 GRIFFIN trial.

The FDA has approved olutasidenib capsules to treat patients with relapsed or refractory acute myeloid leukemia with identified an IDH1-mutation. The label comes with a boxed warning for differentiation syndrome, and a warning for hepatotoxicity.

Nurse investigators created an enteral nutrition standardized pathway for pediatric patients about undergoing hematopoietic stem cell transplantation.

In light of findings from the phase 3 DREAMM-3 trial, manufacturers have elected to withdraw belantamab mafodotin-blmf from the United States market.

Combining ponatinib with reduced-intensity chemotherapy elicited a high rate of minimal residual disease (MRD)-negative complete remissions and no new safety signals in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Patients who receive high cumulative doses of triple intrathecal therapy may be at an increased risk of neurocognitive problems.

Ibrutinib demonstrated encouraging responses for patients with relapsed/refractory mantle cell lymphoma in a real-world setting.

Coadministration CD19- and CD22-directed CAR T-cell therapy produced relatively durable remissions in children with high-risk hematologic or isolated extramedullary relapse of B-acute lymphoblastic leukemia.

The FDA has approved brentuximab vedotin (Adcetris) in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric patients with classical Hodgkin lymphoma.

Cobimetinib is now an FDA-approved therapy for patients with histiocytic neoplasms.

Following CAR T-cell therapy, the onset of hypophosphatemia may represent a biomarker for immune effector cell–associated neurotoxicity syndrome incidence and severity.

Patients with multiple myeloma who have already undergone 4 lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, may now receive treatment with teclistamab-cqyv (Tecvayli).

A multidisciplinary intervention to address financial toxicity led to improved overall survival rates for patients with blood cancers.

A subgroup of the phase 3 GLOW trial revealed a unique relationship between undetectable minimal residual disease status and progression-free survival in elderly or unfit patients with chronic lymphocytic leukemia who received ibrutinib plus venetoclax.

Individuals with AML who underwent a bone marrow transplant are at an increased risk of developing subsequent neoplasms, and other chronic health conditions.

Structured preceptorships promote competence, confidence, and job satisfaction in new oncology nurse practitioners.

Following treatment with rusfertide, patients with polycythemia vera were able to significantly reduce their need for blood draws.

Menstrual suppression can improve outcomes and quality of life in premenopausal women undergoing hematopoietic stem cell transplant.

At a median follow-up of 12.4 months, patients with IDH1-mutated acute myeloid leukemia had achieved a significant improvement in event-free survival with ivosidenib/azacitidine compared with placebo.

Six-year follow-up data showed an overall survival rate of 89% among patients with follicular lymphoma who received either lenalidomide plus rituximab or immunochemotherapy.

A significant portion of patients with lower-risk myelodysplastic syndromes achieved red-blood transfusion independence with luspatercept with no new safety signals.

On September 22 and 23, 2022, the FDA’s Oncologic Drugs Advisory Committee (ODAC) convened for a hearing to assess the risk-benefit ratio of 3 agents.

In a presentation at the 2022 Oncology Nursing Society Bridge, Stephany L. Rodriguez, RN, MS, NP, discussed the later effects associated with hematopoietic stem cell transplant and how to manage them.

Pegfilgrastim-fpgk, a biosimilar medicine of pegfilgrastim, has received FDA approval for patients with non-myeloid malignancies and a clinically significant incidence of febrile neutropenia.

Donna Catamero, ANP-BC, OCN, CCRC, presented on her experience in expanding satellite clinical trial operations during the International Myeloma Society’s 6th Annual Nursing Symposium.

The nurse care pathway outlines best practices for monitoring, and responding to, pneumocystis jirovecii pneumonia risk in patients with multiple myeloma receiving novel, high-risk therapies.